血清VEGF-C、VEGFR-2、3表达水平在急性白血病疗效监测及预后判断中的应用

目的 观察AL患者血清中VEGF-C及VEGFR-2、VEGFR-3表达水平,探讨其临床意义.方法采用酶联免疫吸附法对51例确诊为AL患者、接受治疗观察的43例及16例健康献血者血清中VEGF-C、VEGFR-2、3进行检测.结果 (1)AL患者VEGF-C、VEGFR-2及VEGFR-3水平,较正常对照组高,差异有统计学意义(P<0.01);(2)治疗后完全缓解(CR)组患者VEGF-C和VEGFR-2水平较治疗前降低,差异有统计学意义(P<0.01);治疗后未完全缓解(NR)组患者VEGF-C和VEGFR-2水平较治疗前降低,但差异无统计学意义(P>0.05);(3)治疗后CR组和NR组VEGFR-3水平较治疗前无明显变化(P>0.05);(4)治疗前NR组VEGFR-2、VEGFR-3水平明显高于CR组,具有统计学意义(P<0.01).结论 观察AL患者治疗前后VEGF-C及VEGFR-2、3表达水平,对预后判断、疗效评估和病情监测具有重要临床意义.

Application of Serum VEGF-C,VEGFR-2 and VEGFR-3 Expression Level in Monitoring Curative Effects and Prognosis of Acute Leukemia

Objective To observe expression level of serum vascular endothelial growth factor-C(VEGF-C), VEGF-C receptor-2 and VEGF-C receptor-3 in patients with acute leukemia(AL) and to explore its clinical significance. Methods Enzyme-linked immuno sorbent assay(ELISA) was used to detect the serum expression levels of VEGF-C, VEGFR-2, and VEGFR-3 of 51 patients diagnosed with acute leukemia, 43 patients under medical treatment and 16 healthy blood donors.Results(1) Serum VEGF-C, VEGFR-2, and VEGFR-3 expression levels in AL patients were significantly higher than those in normal control group.(2) Serum VEGF-C and VEGFR-2 expression levels in complete remission(CR) group significantly declined after treatment.Serum VEGF-C and VEGFR-2 expression levels in non-complete remission(NR) group slightly declined after treatment but no significant difference was found(P>0.05).(3) No significant difference was found in serum VEGFR-3 expression levels both in CR group and NR group after treatment(P>0.05).(4) Serum VEGF-C,VEGFR-2, and VEGFR-3 expression levels in NR group were significantly higher than those in CR group before treatment(P<0.08). Conclusions Observing serum expression level of VEGF-C,VEGFR-2,and VEGFR-3 of AL patients may be helpful in monitoring curative effects and prognosis of acute leukemia.